Printer Friendly

Oxford BioMedica sees encouraging results in Phase I/II trial of TroVax.

M2 EQUITYBITES-February 24, 2017-Oxford BioMedica sees encouraging results in Phase I/II trial of TroVax


Oxford BioMedica has seen "encouraging" results from its Phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) in patients with advanced colorectal cancer, the company announced on Friday.

During a poster session at the American Society of Clinical Oncology and Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium held in Orlando, a poster presented by clinical investigators described the open-label Phase I/II clinical trial involving 53 patients with inoperable, metastatic colorectal cancer. The patients were randomised to receive either no treatment, low dose CPM, TroVax only or low dose CPM followed by TroVax.

The study showed that patients given TroVax and low dose CPM demonstrated significant anti-5T4 immune responses by treatment day 43.

Secondary analysis revealed CPM and TroVax given independently induced highly beneficial anti-tumour immune responses, resulting in significant survival of end stage colorectal cancer patients, without any major toxicity.

The company noted that this was the first randomised study to show a benefit of immunotherapy in advanced colorectal cancer patients.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 24, 2017
Previous Article:Medivir's Nomination Committee proposes new board prior to 2017 AGM.
Next Article:AEP and Dynegy enter into ownership transfer agreements.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters